title: Disulfiram neuropathy: a review (1971-1988) and report of a case.
abstract: Neuropathy is one of the most severe side effects of disulfiram therapy. We report the case of a young man who developed a neuropathy following disulfiram administration, with a virtually complete recovery in 14 months. We then discuss 37 cases of disulfiram neuropathy reported since 1971. Evidence is given that: (1) there is no numerical sex prevalence, although the incidence of the disease in women is probably disproportionately high; (2) symptom onset latency is dose-dependent, being longer at 250 mg/day or less; (3) neurological deficits are also dose-dependent, being milder at 250 mg/day or less; (4) the two previous findings and single observations suggest that disulfiram neuropathy is a dose-dependent phenomenon; (5) recovery probably follows a course which depends primarily on the initial degree of impairment; (6) the genetic mechanism probably involves carbon disulfide and a hypothesis as to the possible biochemical mechanism is proposed; (7) chloral hydrate can bear a potentiation effect on neuropathy, and the association with disulfiram is best avoided. Further, we give guidelines for the differentiation between alcoholic and disulfiram neuropathy, advise prescribing the drug at 250 mg daily or less, if possible, and stress the utmost importance of an early diagnosis.
authors.affiliation: Clinica Neurologica dell'Università di Brescia, Ospedale Civile, Italy.
authors.forename: G B
authors.initials: GB
authors.lastname: Frisoni
authors.forename: V
authors.initials: V
authors.lastname: Di Monda
mesh_terms: D000328:Adult; D004221:Disulfiram / Q000009:adverse effects*; D005684:Gait; D006801:Humans; D007866:Leg / Q000294:innervation*; D008297:Male; D009069:Movement Disorders / Q000209:etiology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing
chemical_list: D004221:Disulfiram